While working at CSL, Struan Sutherland led efforts to develop an antivenom to the funnel-web spider and revolutionised treatment of snake bites by developing the pressure-immobilisation first aid technique and the snake venom detection kit. Struan Sutherland was Head of Immunology Research, working at CSL's Parkville site from 1966-94. His interest in venoms was sparked in 1967 by the deaths of a young soldier bitten by a blue-ringed octopus and of a child bitten by a Sydney funnel-web spider. In recognition of his achievements, he was awarded the AMA Prize for Medical Research in 1977 and the James Cook Medal of the Royal Society of NSW in 1984. A prolific author, he published over 300 articles and book chapters throughout his career. Struan Sutherland was honoured posthumously in the 2002 Australia Day awards as an Officer of the Order of Australia.

1983 - Manufacturing of GLANVAC® Vaccine

CSL begins manufacturing GLANVAC® vaccine for the prevention of clostridial diseases and 'cheesy gland' in sheep.

1991 - CSL Limited is Incorporated

CSL Limited is incorporated as a Public Company in April 1991 under the Corporations Law. All shares are held by the Commonwealth Government.

Incoming MD/CEO Dr Brian McNamee states “our main aim is to contribute to national health and wealth by building a great and independent Australian company.”

1992 - CSL signs agreement with Merck to Produce Child Vaccines

CSL signs an agreement with Merck Sharp & Dohme (Australia) Pty Ltd and Merck & Co Inc to develop combination vaccines for children in Australia, New Zealand and the Asia-Pacific region.

CSL Bioplasma commences toll manufacturing for Malaysia.

1993 - Agreement with Commonwealth Government to Produce Plasma-derived Products

CSL enters a 10 year agreement with the Commonwealth for the manufacture and supply of a range of plasma-derived products for Australians.

Production commences at CSL's new plasma products facility - CSL Bioplasma in Broadmeadows.

CSL commences involvement in two Cooperative Research Centres developing and commercialising Australian innovative technology.

1994 - Public Listed in Australian Stock Exchange

Following a public float, CSL is listed on the Australian Stock Exchange on 30th May 1994. Official sale date 3 June 1994.

CSL's Broadmeadows Bioplasma plant is opened. The chromatographic albumin plant included in the facility is the largest in the world.

CSL acquires US cell culture company JRH Biosciences Inc in September 1994. JRH operations merge with CSL's existing cell culture reagents business.

CSL acquires a majority interest in Iscotec AB, a Swedish company with global rights to commercialise a novel adjuvant (to enhance the response to vaccines).

1995 - Veterinary Viral Vaccine Facility Opens in New Zealand

CSL opens New Zealand veterinary viral vaccine facility.

CSL Bioplasma issues the world's first chromatography based albumin product.

1996 - Construction of New Packaging Dispensing Suite Commenced

Construction of new Pharmaceutical Packaging dispensing suite, officially opened on 18 November 1998.

CSL Bioplasma wins "Plant of the Year" award from the Society of the Chemical Industry of Victoria.

1998 - Biocor Animal Health Acquisition

CSL acquires Biocor. The US veterinary vaccine manufacturing plant is acquired on 30 June 1998 in a major step towards developing an international position for CSL's veterinary products.

1999 - CSL Bioplasma signs agreement with American Red Cross

CSL's Bioplasma Division signs a product development and manufacturing agreement with the American Red Cross to complete contract fractionation and co-development of new products.

Privacy | Terms of Use | Employees | Webmaster